Professional Documents
Culture Documents
Please find below the answers to questions received during the lecture.
Don’t hesitate to send any question to me through your group leader.
Good luck
Links to videos :
1. Protein structures
https://www.youtube.com/watch?v=wvTv8TqWC48&t=394s
2. understanding sickle cell anemia
https://www.youtube.com/watch?v=wsykWqyXSKM
3. sickle and mechanism and drug design
https://www.google.com/search?sca_esv=563701320&q=voxelotor+and+sickle&tbm=vid&source=lnms&sa=X&ved=2ahUKEwj
OlqnXgZuBAxWYVqQEHa3TCdEQ0pQJegQIDhAB&biw=1920&bih=923&dpr=1#fpstate=ive&vld=cid:d13eda83,vid:gqx2xJI
qMGo
Why is myoglobin in the muscles? In other words why is it different than the hemoglobin found in blood?
Myoglobin has a different O2 binding properties. They take their oxygen from Hb and store it for muscle needs during exercise.
Biomolecules serve different function depending on their properties.
For more information: https://byjus.com/biology/differentiate-between-hemoglobin-and-myoglobin/
If the medication for preventing the RBCs to become deoxy, then what is the point of the RBCs isn’t the idea is to carry
oxygen to the parts of the body?
Excellent question answer from a study published in 2021(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570057/)
1. Voxelotor therapy reduces sickling and increases hemoglobin, but oxygen delivery to tissues is offset by increased
hemoglobin O2 affinity.
2. Drugs that reduce sickling by increasing HbF or decreasing MCHC should be more effective than drugs that increase O2
affinity.